Blood samples were collected from 30 women with age ranged from 27 -70 years after 3 cycles of chemotherapy. Sera were used for IgA, IgG, IgM, C3, C4, IL-6 and TNF-a estimation. After 3 cycles of chemotherapy, all the immunological parameters reduced except TNF-a. Patients who developed disease reoccurrence after chemotherapy exhibit a significantly higher IgA, C3, IL-6 and TNF-a levels after 3 cycles of chemotherapy than patients who did not (p , 0.05). Therefore, serum IgA, C3, IL-6 and TNF-a can be used as predictors for breast cancer reoccurrence.
Following an activating stimulus, CD4þT-helper cells that are Th1-polarized secrete IFN-g, TNF-a, IL-2, and IL-12, 1 which in turn induce upregulation of antigen processing, can induce expression of MHC class I and II molecules, and can induce other antigen display cofactors in neoplastic cells. Th1 CD4þT-helper cells also enhance antitumor immune responses by secretion of INF-g, which in turn induces activation of macrophage cytotoxic activity. 2 Serum IgA, IgG, IgM, C3, C4, IL-6 and TNF-a were measured for 30 women, aged 27 -70 years. 3, 4 Serum IgA was significantly higher in patients who developed recurrence than patients who did not (p , 0.05) ( Patients who developed recurrence exhibit a higher C4 level than patients who did not; but it was statistically not significant (Table 1) . Patients who developed recurrence exhibit a significantly higher IL-6 level (284.16^33.97 pg/ml) than those who did not (191.58^74.78 pg/ml) (P , 0.05) ( Table 1) . Patients who develped recurrence showed a significantly higher TNF-a level (484.32^357.02 pg/ml) than those who did not (166.41^122.88 pg/ml) (P , 0.05) ( Table 1) . The IgA elevation reflects the load and activity of the melignant cells through host immune modulation or secretion of IgA by their own cells. This gives serum IgA a novel role in breast cancer patients prognosis. Since complement system has been activated through the calssical pathway, 5 C3 can be beneficial in breast cancer prognosis and patients follow up during chemotherapy. IL-6 has an important role in tumour growth and metastasis and can illustrate the extent and the subclinical spread of the disease. Thus, IL-6 can be an important prognostic and predictive marker, as well as a vital treatment target in breast cancer patients. There is significant greater TNF-a level for patients who develop recurrence, in comparison to those who did not. That would be in consistence with the work of Nenova et al., 6 who revealed that cancer recurrence for patients exhibited TNF-a enhancement after third chemotherapy cycle. Therefore, serum TNF-a could be used clinically as a useful tumour marker for disease extent and outcome of breast cancer. In conclusion, serum IgA, C3, IL-6 and TNF-a can be used as a predictors for breast cancer recurrence. 
